[ad_1]
Seoul [South Korea]Nov 24 (ANI/Global Economics): SK Bioscience said on Wednesday that it will not manufacture the finished product of South Korea’s first COVID-19 vaccine ‘Sky Covione’ due to low vaccination rates.
The company previously received project approval on June 29 and supplied the vaccine in September under a pre-purchase contract with the government, but production was suspended due to sluggish market demand.
Read also | Layoff season: Layoffs have hit the global media and entertainment industry amid a slowing economy.
A relevant person in charge of SK Bioscience said: “The production of vaccines is divided into raw liquid and finished products, and the finished products are supplied according to market demand. Sky Covione is currently not producing due to low vaccination rates, and we will resume production later.” The government has requested. “
“We are still waiting for global approval for overseas sales,” the official added.
According to data from the Korea Centers for Disease Control and Prevention, only 493 people were vaccinated against Sky Covione from the 1st to the 20th of this month. During the same period, 54,711 people received the Pfizer vaccine. Far fewer people have received the Sky Covione vaccine than the Pfizer vaccine.
Meanwhile, SK Bioscience applied for conditional marketing authorization (CMA) from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) in July. It also applied for an Emergency Use Authorization (EUA) with the World Health Organization (WHO) in early September to quickly provide vaccines and treatments. However, nothing has been approved yet. (ANI/Global Economy)
(This is an unedited and auto-generated story from a Syndicated News feed, the content body may not have been modified or edited by LatestLY staff)
[ad_2]
Source link